How ClinOps Teams Should Evaluate GenAI Tools in Trial Discovery

In a recent video interview with Applied Clinical Trials, Adrianne Rivard, senior community development manager, myTomorrows, discussed the challenges physicians face in identifying clinical trials. Highlighting insights from a recent myTomorrows report on the need to streamline clinical operations, Rivard touched on the use of artificial intelligence (AI) to streamline pre-screening, which can reduce the need for multiple databases. She also discussed how AI tools are gaining use, necessitating compliance with data privacy standards and ongoing education to build trust among physicians.

ACT: With nearly a third of physicians now using GenAI tools like ChatGPT to aid in trial discovery, how should clinops teams evaluate and validate the accuracy, compliance, and usability of these emerging technologies?

Rivard: It's great to hear that physicians are starting to use GenAI tools, because I think, like everyone else, they had their initial uncertainty of AI. ‘Can I use this? Can I trust this? How does this work?’ I think especially because physicians are using sensitive data, it's good that they're cautious, but I think for anyone using the tools, or encouraging people to use the tools, really need to make sure that they comply with data privacy standards, regulatory frameworks like HIPAA and GDPR. I think another key factor is education, and we also saw this from the survey, that 69% of physicians said that actual training would build better confidence and trust in the AI, so I think providing ongoing education and support is just as important as the technology itself.